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Background: Adenosine leads to atrial action potential (AP) shortening through
activation of adenosine 1 receptors (A1-R) and subsequent opening of G-protein-
coupled inwardly rectifying K+ channels. Extracellular production of adenosine is
drastically increased during stress and ischemia.
Objective: The aim of this study was to address whether the pharmacological
blockade of endogenous production of adenosine and of its signaling prevents atrial
fibrillation (AF).
Methods: The role of A1-R activation on atrial action potential duration, refractoriness,
and AF vulnerability was investigated in rat isolated beating heart preparations
(Langendorff) with an A1-R agonist [2-chloro-N6-cyclopentyladenosine (CCPA), 50 nM]
and antagonist [1-butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36),
40 nM]. Furthermore, to interfere with the endogenous adenosine release, the ecto-5′-
nucleotidase (CD73) inhibitor was applied [5′-(α,β-methylene) diphosphate sodium salt
(AMPCP), 500 µM]. Isolated trabeculae from human right atrial appendages (hRAAs)
were used for comparison.
Results: As expected, CCPA shortened AP duration at 90% of repolarization (APD90)
and effective refractory period (ERP) in rat atria. PSB36 prolonged APD90 and ERP
in rat atria, and CD73 inhibition with AMPCP prolonged ERP in rats, confirming
that endogenously produced amount of adenosine is sufficiently high to alter atrial
electrophysiology. In human atrial appendages, CCPA shortened APD90, while PSB36
prolonged it. Rat hearts treated with CCPA are prone to AF. In contrast, PSB36 and
AMPCP prevented AF events and reduced AF duration (vehicle, 11.5 ± 2.6 s; CCPA,
40.6 ± 16.1 s; PSB36, 6.5 ± 3.7 s; AMPCP, 3.0 ± 1.4 s; P < 0.0001).
Conclusion: A1-R activation by intrinsic adenosine release alters atrial electrophysiology
and promotes AF. Inhibition of adenosine pathway protects atria from arrhythmic events.
Keywords: adenosine, A1-R, arrhythmias, CD73, hypoxia, translational models
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INTRODUCTION
G-protein-coupled inwardly rectifying K+ channels (GIRK) play
a key role in the physiological regulation of the heart. GIRK
channels are in part responsible for the vagus-induced negative
chronotropy upon muscarinic receptor (M2-R) activation
(Pfaffinger et al., 1985; Sato et al., 1990), and their current
is therefore referred to as IK,ACh. Constitutive activation of
these channels in the absence of muscarinic agonists has been
implicated in human persistent AF (Dobrev et al., 2005).
Apart from being activated through muscarinic receptors, recent
evidence has shown that adenosine, via the A1-receptor (A1-R),
also increases GIRK channel conductance (Wang et al., 2013;
Li et al., 2016). In the atrium, GIRK channel activation
causes resting membrane potential (RMP) hyperpolarization
and shortens both action potential duration (APD) and
effective refractory period (ERP). Since the shortening of APD
and refractoriness represents hallmarks of pro-arrhythmicity,
adenosine can evoke atrial arrhythmias in humans, as well as
in animal models (Drury and Szent-Gyorgyi, 1929; Belhassen
et al., 1984; Kabell et al., 1994; Bertolet et al., 1997; Strickberger
et al., 1997; Tebbenjohanns et al., 1997). For this reason,
adenosine can be used as a tool to detect the location of
possible AF foci during ablation procedures (Li et al., 2016;
Letsas et al., 2017).
Adenosine is a purine nucleoside produced from
adenosine monophosphate (AMP) by the glycosyl
phosphatidylinositol-anchored membrane ectonucleotidase
CD73, catalyzing the dephosphorylation of AMP to adenosine
(Colgan et al., 2006). CD73 has been associated with
cardioprotection during ischemia and hypoxia (Eckle et al.,
2007), as extracellular adenosine functions as a protective
metabolic signal following oxygen demand (Fox et al., 1974;
Haneda et al., 1989). Adenosine is released upon energy
perturbations, such as ischemia or hypoxia, and its extracellular
levels are subsequently fine-tuned by the activity of transporters
and enzymatic cascades (Eltzschig et al., 2013). Adenosine
levels are limited in time and space by a fast conversion to
the metabolite inosine by adenosine deaminase, as well as
adenosine reuptake and subsequent phosphorylation to AMP
by the equilibrative nucleoside transporters and adenosine
kinase, respectively (Moser et al., 1989; Sheth et al., 2014).
During normoxia, systemic adenosine levels have been reported
to be stable around ∼21 nM (Saito et al., 1999), while during
cardiac injury and heart failure, adenosine levels can increase
sevenfold (Funaya et al., 1997). Purinergic signaling is under
control of the transcription factor hypoxia inducible factor-1α
(HIF-1α) (Thompson et al., 2004; Eltzschig et al., 2013). In
normoxic conditions, prolyl hydroxylases degrade HIF-1α
via ubiquitine-proteasome degradation consuming oxygen,
resulting in low adenosine levels (Semenza, 2011). During
hypoxia, low oxygen levels reduce the activity of prolyl
hydroxylases, stabilizing HIF-1α, which translocates into the
cell nucleus and upregulates CD73 (Eltzschig and Carmeliet,
2011). Moreover, HIF-1α downregulates transcription of the
nucleoside equilibrative transporters and adenosine deaminase
(Eltzschig et al., 2013). Therefore, hypoxia increases adenosine
availability, slows adenosine metabolism rate, and, thereby,
increases adenosine receptor activation.
Four types of adenosine receptors are expressed in the
heart (A1, A2A, A2B, and A3), which can also function as
heterodimers in both physiological and pathological conditions
(Headrick et al., 2011). A1-R is a Gi-protein-coupled receptor
and is predominantly expressed in atrial and nodal tissue (Pelleg
et al., 1987; Belardinelli et al., 1995). In the atrioventricular
(AV) node, adenosine slows the heart rate. This is partly
accomplished by the activation of GIRK channels through
the Giβγ-subunits and partly by the reduction in cyclic
adenosine monophosphate (cAMP) through the Giα-subunit.
Reduced cAMP levels decrease hyperpolarization-activated cyclic
nucleotide-gated (HCN) channel activity in pacemaker cells
and decrease protein kinase A activity, thereby reducing L-type
calcium current (Belardinelli and Isenberg, 1983; Belardinelli
et al., 1989, 1995; Pelleg et al., 1990). This process leads
to a slowing of AV conduction (Belardinelli et al., 1995).
For this reason, adenosine is used in clinical practice to
terminate supraventricular tachycardia, such as atrioventricular
nodal reentrant tachycardia (AVNRT) (DiMarco et al., 1990;
Tebbenjohanns et al., 1997). However, the upregulation of A1-R
in the failing sinoatrial (SA) node has been associated with
an increase in AF in a canine heart failure model (Lou et al.,
2014). AF drivers anchor to heterogeneity regions, which can
also be anatomically determined (Haissaguerre et al., 2016).
A large area of structural and electrical heterogeneity has been
identified between the SA node complex and the surrounding
right atrial tissue (Swarup et al., 2014). In addition, impairment
in SA node conduction causes electrical remodeling and fibrosis,
leading to micro-reentry circuits, which promote initiation and
maintenance of AF (Thery et al., 1977; Kistler et al., 2004;
Sanders et al., 2004).
AF is associated with heart failure and thromboembolic
diseases (Rienstra et al., 2004). Moreover, AF patients’ daily life
is often affected due to exertional dyspnea and reduced exercise
tolerance (Hagens et al., 2004; Rienstra et al., 2004). In fact,
it has been shown that oxygen uptake is significantly lowered
in AF patients during exercise (Takano et al., 2019). Normoxic
conditions play a fundamental role in atrial physiological
function (Schuttler et al., 1983). Reduced supply of oxygen
in localized atrial regions of a canine acute model showed
a profound conduction slowing, which promoted reentry
mechanisms (Sinno et al., 2003). In addition, more evidence
highlight the role of hypoxia/ischemia in AF. In a case study
of inferior infarction, AF spontaneously terminated after atrial
branch reperfusion (Bunc et al., 2001). Isolated atrial tissues from
AF patients showed a higher degree of fibrosis and vessel density
(Gramley et al., 2010). Moreover, AF tissues express higher
amount of typical hypoxic markers, such as HIF-1α and vascular
endothelial growth factor (VEGF) (Gramley et al., 2010). It has
also been proposed that fibrosis, upon structural remodeling in
AF, might increase the diffusion distance of oxygen through the
tissue and chronically trigger hypoxic and ischemic signaling
(Mihm et al., 2001; Gramley et al., 2010).
In this study, we scrutinized the electrophysiological effects of
intrinsic adenosine release, as well as extrinsic A1-R activation,
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in rat heart and human atrial tissue. We show that the
activation of A1-R not only shortens atrial APD and ERP
but also promotes AF susceptibility and duration. In contrast,
antagonizing the activation of A1-R, or pharmacologically
impairing the intrinsic adenosine release by inhibition of CD73,
protects against arrhythmias.
MATERIALS AND METHODS
Electrophysiological Recordings in
Langendorff Preparation From Rat
Hearts
Animal experiments were performed according to the ethical
standards of the Danish Research Animal Committee (license
no. 2012/152934-00345) and in accordance with the Danish
legislations. A total of 38 male Wistar rats, 300–400 g, were
anesthetized with sodium pentobarbital (40 mg/kg IP). By
means of a tracheostomy, the rats were ventilated (4 ml/60
strokes/min) through a ventilator (7025 Rodent ventilator, Ugo
Basile, Comerio VA, Italy). To remove the hearts, a thoracotomy
was performed. Through a small aortic transection close to the
aortic arch, the hearts were cannulated and connected to the
Langendorff retrograde perfusion system (Hugo Sachs Elektronik
-Harvard Apparatus GmbH, March-Hugstetten, Germany). The
hearts were perfused at a constant pressure of 80 mmHg with a
37◦C, pH 7.4, Krebs–Henseleit buffer (in mmol/L) NaCl 120.0,
NaHCO3 25.0, KCl 4.0, MgSO4 0.6, NaH2PO4 0.6, CaCl2 2.5,
glucose 11.0, at constant oxygenation with a O2/CO2 mixture
of 95/5%. The aforementioned devices were connected to an
amplifier (Hugo Sachs Elektronik -Harvard Apparatus GmbH,
Germany). Epicardial monophasic action potential (MAP)
electrodes (Hugo Sachs Elektronik -Harvard Apparatus GmbH,
March-Hugstetten, Germany) were placed on the left and right
atria. The electrocardiogram (ECG) was obtained with three ECG
electrodes (Hugo Sachs Elektronik -Harvard Apparatus GmbH,
March-Hugstetten, Germany) placed in close proximity to the
heart. The hearts were immersed into a temperature-controlled
bath containing the above-mentioned buffer. The pacing stimuli
were twice the diastolic threshold with a duration of 2 ms.
A pacing electrode was placed on the atrium, and the heart
was allowed to stabilize for 30 min before recording the
electrophysiological parameters. After baseline measurements,
each group was perfused with a drug [final concentration,
2-chloro-N6-cyclopentyladenosine (CCPA) 50 nM, 1-butyl-3-
(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36) 40 nM,
5′-(α, β-methylene) diphosphate sodium salt (AMPCP) 500 µM].
After stabilization, hearts were paced for 5 min with a cycle
length (CL) of 200, 150, and 100 ms, respectively. At each
pacing rate, diastolic threshold (DT)—applied field stimulation
to elicit an action potential—was evaluated and doubled. To
measure the ERP at different pacing rates, the delay (1S2
− S1) between the normal electrical stimulus (S1) and an
additional stimulus (S2) was increased until an AP occurred. To
measure the atrioventricular Wenckebach point—block of AV
nodal conduction—the pacing rate was increased until second-
and/or third-degree AV block occurred. To evaluate intrinsic
rhythm, pacing was switched off for 3 min. At a CL of 100 ms,
high-frequency electrical pacing (CL of 10 ms, for 500–1,000 ms,
twice the DT) for inducing AF was applied up to 20 times
every 3–5 s. AF episode duration was calculated from the end
of electrical stimulation to the termination of the arrhythmic
event—evaluated as a rapid atrial firing longer than 0.5 s.
All data were acquired using the 16-channel PowerLab system
(ADInstruments Ltd., Dunedin, New Zealand) (Figures 1A,B).
Electrophysiological Recordings in
Human Intact Cardiac Atrial Muscles
The investigation on human samples conforms to all principles
outlined by the Declaration of Helsinki and the Medical
Association of Hamburg (Germany). According to the guidelines
of the ethical review committee of the Medical Association
of Hamburg, there is no need for a specific approval in this
case, since patient data were used anonymized. All materials
from patients were taken with informed consent of the donors.
Eleven intact cardiac muscles from the right atrial appendages
(RAAs) were obtained from 11 patients in sinus rhythm
(SR) undergoing coronary artery bypass surgery and/or valve
replacement (Supplementary Material 1). Atrial APs were
recorded with intracellular microelectrodes in the right atrial
trabeculae (microelectrode tip resistance, 10–25 M; 1-ms
stimulus, 25% above DT). The bath solution contained (in
mmol/L): NaCl 127.0, KCl 4.5, MgCl2 1.5, CaCl2 1.8, glucose 10.0,
NaHCO3 22.0, and NaH2PO4 0.42, equilibrated with O2/CO2
mixture of 95/5% at 37◦C, pH 7.4. All data were acquired
using the PowerLab system (ADInstruments Ltd., Dunedin,
New Zealand). Drugs were applied using a fast perfusion
system. Tissues were allowed to stabilize for 30 min at least.
Afterward, the trabeculae were electrically paced during the
entire experiment at CL of 1,000 ms. Baseline was recorded
for 5 min before the administration of 1 µM CCPA or 1 µM
PSB36. ERP was measured at baseline and after 10 min of drug
superfusion (Figure 1C).
Compounds
Experiments were conducted using the A1-R agonist CCPA
(Tocris Bioscience Cat. No. 1705, Abingdon, United Kingdom)
dissolved in a mixture of dimethyl sulfoxide (DMSO—Sigma
Aldrich Cat. No. PHR1309) and distilled water (ratio 1:100),
the A1-R antagonist PSB36 (Tocris Bioscience Cat. No.
2019, Abingdon, United Kingdom) dissolved in a mixture of
DMSO and distilled water (ratio 1:100), the CD73 inhibitor
AMPCP (Tocris Bioscience Cat. No. 3633, Abingdon,
United Kingdom) dissolved in distilled water. DMSO (1%)
was used as vehicle (Figure 1A).
Data Analysis
Data are presented as mean ± SEM. All Langendorff and
human AP measurements data were analyzed using Labchart 7
(ADInstruments, Ltd., Dunedin, New Zealand).
Statistical analysis was performed in GraphPad Prism 7
(GraphPad Software, La Jolla, CA, United States). Two-tailed
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FIGURE 1 | (A) Adenosine (Ado) pathway in cardiomyocytes. Adenosine release is regulated by the ectonucleotidases CD39 and CD73. CD39 converts ATP and
ADP into AMP, while CD73 converts AMP into adenosine. Extracellular adenosine half-life is determined by adenosine deaminase (ADA) conversion to inosine (Ino) or
internalization by specific equilibrative nucleoside transporters (ENT). A1-receptor activation increases K+ permeability for the G-protein-coupled inwardly rectifying
K+ (GIRK) channel through the Gβγ and inhibits the adenylyl cyclase (AC) through Giα subunit. 2-Chloro-N6-cyclopentyladenosine (CCPA) is a potent A1-R agonist;
1-butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36) specifically antagonizes A1-R signaling. 5′-(α,β-methylene) diphosphate sodium salt (AMPCP)
inhibits CD73. (B) Experimental protocol on isolated perfused male Wistar rat hearts. Hearts were removed and placed on the Langendorff configuration. After
stabilization phase and baseline, hearts were perfused with vehicle, CCPA, PSB36, or AMPCP, respectively. Each group was paced at CL of 200, 150, and 100 ms.
At the end of each experiment, the hearts were exposed to high-frequency pacing events in order to induce AF. (C) Experimental protocol on intact contracting
muscles from human right atrial appendages (hRAAs). Human atrial tissues were paced at CL of 1.0 s. After stabilization phase, baseline was recorded for 5 min.
After that, hRRAs were exposed to CCPA or PSB36, respectively, for 10 min.
paired t-tests were used to compare baseline with the effect
of vehicle, CCPA, PSB36, and AMPCP on intrinsic rhythm,
Wenckebach point APD90, and ERP. All detailed statistics
of isolated heart data are presented in the Supplementary
Material 2. AF duration values of each group were analyzed
through a relative cumulative distribution (bin center, 1.0 s)
by non-parametric Kruskal–Wallis test. Following, the Dunn’s
multiple comparisons posttest was used to compare vehicle
with the treated groups. P < 0.05 were considered statistically
significant (denoted by asterisks in figures). Values of P < 0.01
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and P < 0.001 are denoted by ∗∗ and ∗∗∗, respectively. Schemes
were drawn with ChemBioDraw Ultra 12.0 (PerkinElmer,
Waltham, MA, United States).
RESULTS
Isolated heart studies in Langendorff configuration allow for
exploration of the cardiac effects of a biochemical pathway in
isolation from the rest of the body. To study the effects of
adenosine signaling in the atrium, we exposed the heart to vehicle
(n = 10), the specific A1-R agonist CCPA (n = 11), the A1-R
antagonist PSB36 (n = 10), and the specific CD73 antagonist
AMPCP (n = 7) (Figure 1).
Effect of A1-R on Chronotropy
The intrinsic rhythm was measured by electrocardiogram (RR
on ECG) (Figures 2A,B). The administration of DMSO did
not affect heart rate. As expected, the A1-R agonist CCPA
produced a profound negative chronotropic effect. In contrast,
perfusion with the specific A1-R antagonist PSB36 produced
a non-significant positive chronotropic effect (P = 0.056).
Increased concentration of both CCPA (>50 nM) and PSB36
(>80 nM) produced runs of tachycardia as well as other
arrhythmic activities (data not shown). No significant difference
in beating rate was detected when the 5′-ecto-nucleotidase CD73
was inhibited with AMPCP (Figures 2A,B).
Diastolic Threshold
The diastolic threshold (DT) is a measure of excitability of
the atrial tissue (Figure 2C). While DT did not change in the
vehicle group, the perfusion with CCPA increased membrane
excitability, showing a significant DT reduction when the heart
was paced at cycle length (CL) of 200 ms and a tendency toward
reduction in DT at CL of 150 and 100 ms. By contrast, PSB36
increased DT at CLs of 200 and 150 ms. AMPCP-treated atria
showed a tendency toward increased DT; however, this did not
reach significance.
Wenckebach Point
To detect whether targeting of the purinergic system affects the
electrical conduction between atria and ventricles, we increased
the pacing rate until the atrioventricular Wenckebach point was
reached. Hearts treated with vehicle did not show any difference
from baseline. Not surprisingly, the activation of A1-R with
CCPA prolonged the Wenckebach point. PSB36, antagonizing
A1-R, showed a slight tendency in reducing the Wenckebach
point, while no effect was observed on the atrioventricular
conduction when CD73 was inhibited with AMPCP (Figure 2D).
Action Potential Duration
To investigate the effect on APD at 90% of repolarization
(APD90) in the atria, the hearts were paced at CLs of 200,
150, and 100 ms for 5 min (Figure 3A). As expected, APD90
moderately decreased as pacing decreased (Supplementary
Material 3). Atrial APD was not altered by the administration
of the vehicle (Figure 3B). CCPA provoked a profound
APD90 reduction at CL of 200, 150, and 100 ms (Figure 3C
and Supplementary Material 4). CCPA showed a maximum
APD90 shortening of ∼51% in dose–response relationship tests
(Supplementary Material 5).
On the other hand, PSB36 showed a tendency to prolong
the atrial APD90 in a rate-dependent manner (Supplementary
Material 4). The prolongation was significant at CL of 150 ms
(Figure 3D). The inhibition of CD73 showed a tendency in
APD90 increase (Figure 3E).
Effective Refractory Period
Hearts treated with vehicle did not change ERP over time, while
CCPA significantly shortened ERP at CLs of 150 and 100 ms
(Figures 4A–C). A1-R inhibition by PSB36 showed the opposite
effect, prolonging ERP significantly in a rate-dependent manner
at CLs of 200 and 150 ms, and with a tendency at CL of
100 ms (Figure 4D). AMPCP induced a significant prolongation
of refractoriness at CLs of 200 and 150 ms, but not at CL of
100 ms (Figure 4E).
Induction of Atrial Fibrillation
To induce AF, the hearts were exposed to fast electrical pacing
(Figure 5A). AF duration for hearts treated with vehicle
(11.5 ± 2.6 s, n = 9) were compared to CCPA (40.6 ± 16.1 s,
n = 10), PSB36 (6.5 ± 3.7 s, n = 10), and AMPCP (3.0 ± 1.4 s,
n = 7). PSB36 and AMPCP significantly shortened the duration
of AF events compared to vehicle, while CCPA increased the
duration of AF. The relative cumulative stratification (in %) of
AF event duration frequencies for each group showed that∼90%
of PSB36 and 85% of AMPCP-treated hearts had AF events
lasting <2 s, in contrast to ∼72% of vehicle and only ∼53% of
CCPA hearts (P < 0.0001 within the groups) (Figure 5B and
Supplementary Material 6). In addition, spontaneous AF (sAF)
events occurred more frequently in CCPA-treated hearts than
in the PSB36 and AMPCP groups (Supplementary Material 7).
Moreover, when atria were not paced, the duration of sAF
events in PSB36 and AMPCP groups was drastically reduced and
significantly lower compared to CCPA-treated hearts (P < 0.05)
(Supplementary Material 8).
Action Potential Duration in Human Right
Atrial Appendage Trabeculae
Action potential measurements were conducted on intact
contracting muscles isolated from the right atrium appendage
of patients in SR. After stabilization, 1 µM CCPA or PSB36
were superfused for 10 min (Figure 1C). CCPA produced a
relative APD90 shortening of ∼12% (Supplementary Material
9) when paced at CL of 1,000 ms (baseline 364.9 ± 25.3 ms
vs. CCPA 320.5 ± 20.2 ms, P < 0.01) (Figures 6A–C). A1-R
inhibition by PSB36 showed a relative APD90 prolongation of
∼9% (baseline 383.6 ± 23.5 ms vs. PSB36 416.9 ± 24.5 ms,
P < 0.001; Figures 6D–F). ERP recordings on isolated human
trabeculae are technically demanding, as extra stimuli often
result in loss of seal. Collected data and statistics are shown in
Supplementary Material 10.
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FIGURE 2 | Chronotropic and dromotropic effects in rat hearts. (A) ECG lead II recordings under intrinsic rhythm. The R–R interval has been used to calculate heart
rate. Paired t-tests between the baseline and the drugs were performed to evaluate significant differences. (B) Chronotropic effect of vehicle,
2-chloro-N6-cyclopentyladenosine (CCPA), 1-butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36), and 5′-(α,β-methylene) diphosphate sodium salt
(AMPCP) (gray, red, blue, and purple dot plots, respectively). White dot plots represent the baseline. Values are presented as mean ± SEM. (C) Effect of vehicle,
CCPA, PSB36, and AMPCP on the diastolic threshold (DT), respectively. (D) Effect of vehicle, CCPA, PSB36, and AMPCP on Wenckebach’s point, respectively.
Vehicle did not affect atrio-ventricular node conduction. CCPA significantly increased Wenckebach point. PSB36 slightly reduced Wenckebach’s point. AMPCP had
no effect on AV node conduction. *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 3 | (A) Atrial monophasic action potentials (MAPs) paced at cycle length (CL) of 150 ms before and after the administration of vehicle,
2-chloro-N6-cyclopentyladenosine (CCPA), 1-butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36), or 5′-(α,β-methylene) diphosphate sodium salt
(AMPCP); black MAPs refer to the baseline, while gray, red, blue, and purple MAPs represent hearts perfused with vehicle, CCPA, PSB36, and AMPCP, respectively.
(B) Effect of vehicle on APD90 at CL of 200, 150, and 100 ms. (C) CCPA shortened APD90 at CL of 200, 150, and 100 ms, respectively. (D) PSB36 showed a
prolongation of APD90 at CL of 200, 150, and 100 ms. (E) Effect of AMPCP on APD90 at CL of 200, 150, and 100 ms. *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 4 | (A) Effective refractory period (ERP) monophasic action potentials (MAPs) of baseline and the relative treated hearts are shown superimposed. (B) Effect
of vehicle on ERP at cycle length (CL) 0.20, 0.15, and 0.10 s. (C) 2-Chloro-N6-cyclopentyladenosine (CCPA) shortened refractoriness at CL of 200 ms, significantly
at CL of 150 and 100 ms. (D) 1-Butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36) prolonged ERP at CL of 200 and 150 ms. (E) 5′-(α,β-Methylene)
diphosphate sodium salt (AMPCP) prolonged ERP at CL of 200 and 150 ms, but not at 100 ms. *p < 0.05, **p < 0.01.
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FIGURE 5 | Induction of atrial fibrillation (AF) through high-frequency electrical pacing. (A) Atrial monophasic action potentials (MAPs) and pacing traces are shown.
Vehicle produced short AF events; by contrasts, 2-chloro-N6-cyclopentyladenosine (CCPA) made the heart prone to sustained AF events.
1-Butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine (PSB36) and 5′-(α,β-methylene) diphosphate sodium salt (AMPCP) reduced atrial sensitivity to high
frequency electrical pacing (Supplementary Material 6; p < 0.0001). (B) Relative cumulative distribution (in%) of AF duration of each group and dot plot of AF
duration events on a logarithmic scale, which shows the range of AF duration among groups when events are different from 0 s. Vehicle, CCPA, PSB36, and AMPCP
are depicted in black, red, blue, and purple, respectively.
Frontiers in Physiology | www.frontiersin.org 9 June 2020 | Volume 11 | Article 493
fphys-11-00493 June 11, 2020 Time: 20:43 # 10
Soattin et al. Adenosine Pathway Inhibition Prevents AF
FIGURE 6 | (A) A1-R activation in human right atrial appendages (hRAAs). APD90 measurements are shown over time when an isolated contracting atrial muscle
was superfused with 1 µM 2-chloro-N6-cyclopentyladenosine (CCPA). (B) Baseline and CCPA-treated hRAA action potentials (APs) were superimposed to show the
APD shortening due to A1-R activation. hRAA was paced at cycle length (CL) of 1.0 s. (C) CCPA shortened APD90 in hRAAs. (D) A1-R blockade in hRAAs. APD90
measurements are shown over time when an isolated contracting atrial muscle was superfused with 1 µM 1-butyl-3-(3-hydroxypropyl)-8-(3-noradamantyl)xanthine
(PSB36). hRAA was paced at CL of 1,000 ms. (E) Baseline and PSB36-treated hRAA APs were superimposed to show the APD prolongation due to A1-R blockade.
(F) PSB36 prolonged APD90 in hRAAs. Resting membrane potential (RMP) in representative panels (B,E) was normalized to show change in AP duration. **p < 0.01,
***p < 0.001.
DISCUSSION
Adenosine plays a key role in cardiac electrophysiology, which
becomes especially prominent during hypoxia or ischemia. In the
heart, adenosine activity is mediated by the aforementioned four
types of adenosine receptors (Headrick et al., 2011). Although
A2A-R also has been associated with AF (Hove-Madsen et al.,
2006; Llach et al., 2011; Molina et al., 2016), the present
manuscript focuses on A1-R as the most likely candidate involved
in the relation between adenosine and AF (Belardinelli and
Isenberg, 1983; Visentin et al., 1990; Kabell et al., 1994; Atienza
et al., 2006; Ip et al., 2013; Li et al., 2016). In fact, A1-R has a
higher expression in the atrium and nodal tissue compared to
the other adenosine receptors (Headrick et al., 2011; Lou et al.,
2014). Generally, A1-R and A2A-R are activated at nanomolar
concentrations of adenosine and therefore show the highest
affinity for adenosine compared to A2B-R and A3-R (low-affinity
receptors), which exhibit their activity during hypoxic stress,
when adenosine levels elevate drastically (Fredholm et al., 2001;
Latini and Pedata, 2001; Pedata et al., 2001). In addition, it
has also been shown that A1-R and A3-R stimulation would
neutralize A2A-R signaling in the heart (Talukder et al., 2002;
Headrick et al., 2011).
We used the specific A1-R agonist (CCPA) and antagonist
(PSB36) that have potent and strong selectivity for A1-R and
have very poor or no selectivity for the other adenosine receptors
(Muller and Jacobson, 2011). Off-target effects through the other
adenosine receptors are therefore unlikely in the present study.
Activation of A1-R increases potassium conductance through
GIRK channels. These channels also play a pivotal role in the
nodal tissue. Our experiments confirm that A1-R activation
also activates GIRK channels in the nodes, as A1-R stimulation
with CCPA showed a clear negative chronotropic effect and
an increase in the Wenckebach point in rat isolated hearts.
As previously shown, when A1-R is genetically deleted, the
drop in heart rate normally induced by adenosine infusion is
abolished (Koeppen et al., 2009). In our work, the inhibition
of A1-R by PSB36 did not produce neither significant nor
biologically relevant elevation in intrinsic rate (P = 0.056) of
isolated perfused hearts, indicating a minor, or absent, effect of
endogenous produced adenosine on the sinus node function. In
addition, the Wenckebach point was not altered following PSB36
infusion, indicating that the AV node is also not affected by
endogenous adenosine.
In the atria, we found that the activation of A1-R with CCPA
profoundly shortened APD90 in both explanted rat hearts and
human trabeculae. ERP was also shortened by CCPA in rat hearts.
Several studies have shown that the prolonged stimulation of
A1-R triggers desensitization of the receptors due to inactivation
and internalization mechanisms (Saura et al., 1998; Klaasse
et al., 2008). However, in our experiments, we did not observe
effects indicating A1-R desensitization (Supplementary Material
11). Although it is not possible to exclude the role of other
potassium channels, the observed effects at the beginning of
the action potential might reflect changes in early IK,ACh (Tang
et al., 2015). For instance, activation or inhibition of A1-R
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could also trigger fluctuations of cAMP levels, which might
affect L-type calcium channels (Headrick et al., 2011). However,
minor changes were detected on the action potentials in our
experiments. Moreover, it has been shown that the adenosine-
induced decrease in ICa currents, via cAMP, would have a
limited or no effect on the shortening of the action potential
(Visentin et al., 1990).
In our work, the relative APD90 shortening appeared
more profound in rats than in humans. Recently, Li et al.
(2016) showed that in humans A1-R and GIRK4 protein
expression follows a gradient with a maximum level in the
superior lateral region of the right atrium. While we only
had access to the right atrial appendage from SR patients,
exposure to CCPA revealed a significant AP shortening.
Interestingly, PSB36 prolonged the APD90 in both rat
and human atria. In addition, the direct antagonism of
A1-R prolonged ERP in isolated rat hearts. This suggests
that adenosine is intrinsically released and contributes to
fine-tuning of the repolarization phase of the atrial action
potential. Several groups have already described intrinsic
and endogenous release of adenosine (Mubagwa et al., 1996;
Headrick et al., 2003; Jammes et al., 2015). To confirm the
electrophysiological effect of this phenomenon, we targeted the
upstream adenosine releasing mechanism with the selective
CD73 inhibitor (AMPCP). AMPCP had a tendency to
prolong APD90 and significantly prolonged ERP, suggesting
that adenosine is intrinsically released under the chosen
experimental conditions.
Atrial fibrillation events were induced with an average
duration of ∼12 s in rat hearts treated with vehicle. The A1-R
agonist (CCPA) made the hearts more prone to AF, increasing
the duration of AF to ∼41 s. In addition, spontaneous AF events
occurred more frequently in CCPA-treated hearts rather than in
the PSB36 and AMPCP groups. Both the direct antagonism of the
A1-R with PSB36 and the inhibition of the CD73 with AMPCP
profoundly reduced the ability to induce sustained AF events.
Interestingly, the activation of A1-R with CCPA
significantly lowered the DT. This could be explained by an
increased GIRK channel activity, hyperpolarizing the resting
membrane potential (Supplementary Material 12A), thereby
increasing the fraction of available sodium channels. Such an
increased sodium current, combined with shorter refractory
periods, would be expected to increase vulnerability and
sustainability of AF. In contrast, antagonizing A1-R with
PSB36 produced a profound reduction in atrial excitability,
represented by an increase in DT. This could suggest an
increased protection from ectopic firing or focal partial
depolarization. Thus, antagonizing A1-R with PSB36 produces
an antiarrhythmic state by prolonging APD and ERP, potentially
supported by a depolarization of RMP (Supplementary
Material 12B), thereby reducing the availability of sodium
channels and thereby susceptibility to triggered activity
(Wang et al., 2013).
During hypoxic and ischemic injury, adenosine reduces
energy consumption and adapts the tissue to hypoxic conditions
(Eltzschig et al., 2013). Based on this, it can be speculated
that the shortening of APD in the atrium, evoked by A1-R
activation resembles a protective mechanism to avoid calcium
overload during cardiac metabolic stress (Cole et al., 1991;
Findlay, 1994). However, even though adenosine protects from
ischemic and hypoxic heart injuries in the ventricles, hypoxic
conditions in the atria may constitute a substrate for AF through
A1-R activation. Hypoxia and ischemia in the heart are cause of
excessive energy consumption. To make matters worse, the high
frequency of atrial excitation and contraction in AF increases
oxygen consumption while limiting oxygen supply to the tissue
(Harada et al., 2017). In this setting, atrial A1-R activation,
especially in regions with high density of GIRK channels, may
constitute an important promoting and sustaining factor for
AF. Recent clinical trials with IK,ACh blockers did not show a
reduction in paroxysmal AF (Podd et al., 2016). However, it
has been shown that obstructive or central sleep apnea causes
AF and atrial remodeling. The reiterated oxygen drop due to
sleep apnea may recruit the purinergic pathway leading to A1-
R stimulation in the atrium as AF substrate (Caples and Somers,
2009; Zhang et al., 2015). Thus, blocking endogenous adenosine
production or inhibiting A1-R activation could be a potential
treatment modality of AF. Pilot studies in rat Langendorff
hearts indicated that, during AF, the acute A1-R blockade
might restore the sinus rhythm (Supplementary Material 13).
However, due to its relatively ubiquitous expression, targeting
the purinergic signaling may have undesirable consequences
on multiple related pathways and organs (Jacobson and Gao,
2006). Therefore, thorough electrophysiological investigations
of adenosine block and A1-R inhibition are needed in intact
AF animal models. In addition, further studies on energy
consumption and calcium handling upon A1-R stimulation could
better clarify the substantial role of the purinergic system in atrial
electrophysiology.
Targeting CD73 for AF treatment appears to be promising.
CD73 inhibition prolonged refractoriness and protected rat atria
from sustained arrhythmogenic events. CD73 has been also
identified as a target for pharmacotherapy strategies of breast
cancer (Stagg et al., 2010), and it plays critical role during
injury protection in the renal proximal tubule as well as in
immune processes, such as inflammation (Antonioli et al., 2013;
Sung et al., 2017). Furthermore, adenosine modulates vascular
homeostasis, also in the heart (Koszalka et al., 2004; Headrick
et al., 2011). Hence, non-beneficial side effects might limit the
efficacy of CD73 as a target for AF treatment.
STUDY LIMITATIONS
The use of rodents as translational model for AF carries study
limitations regarding differences with human physiology. To
repolarize the action potential, unlike humans, rodents rely
on IK,to currents, which accelerate the repolarization rate and
shorten the plateau phase (Roden, 1998; Guo et al., 1999).
However, sufficient parallels in pathophysiology of cardiac
diseases have been found between rodents and humans, so
that rodents can be considered a valid model for cardiac
electrophysiology and AF (Nishida et al., 2010; Diness et al., 2011;
Farraj et al., 2011; Skibsbye et al., 2011, 2015).
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Although the number of patients represents an important
limitation to this study in terms of statistical and clinical
significance, human trabeculae in SR were a useful investigation
tool to validate data obtained in rat isolated perfused hearts
showing an important translational level of confidence between
rodents and human physiology.
The use of Krebs–Henseleit and Tyrode buffers for
Langendorff and Steiert organ bath experiments, respectively,
may have generated a slight hypoxic environment over time.
This may have contributed to the intrinsic release of adenosine.
However, hypoxic conditions cannot be assessed in the systems
used in this study. During perfusion and superfusion experiments
of vehicle, CCPA, or PSB36, the effect of the intrinsic adenosine
release on A1-R was not measured. However, adenosine’s half-life
is extremely short, and the dissociation equilibrium constants
between adenosine, CCPA, and PSB36 for A1-R (700, 0.4, and
0.7 nM, respectively) (Lohse et al., 1988; Bilkei-Gorzo et al., 2008;
de Lera Ruiz et al., 2014) would favor the binding of CCPA
or PSB36 to A1-R rather than the natural occurring purine
nucleoside. The choice of drugs concentration was based on
previous laboratory data (not shown) and recent literature.
CONCLUSION
In this study, we highlighted the role of adenosine signaling in
atrial electrophysiology and AF susceptibility. Reducing A1-R
activation, either by direct inhibition or by interfering with
endogenous adenosine release, produced an antiarrhythmic
state of the atria. These data reveal CD73 as a potential
pharmacological target in the setting of AF.
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